title: Disposition of antipyrine in patients with extensive metastatic liver disease.
abstract: In the present study the effect of metastatic liver disease on hepatic drug metabolism has been examined by studying the pharmacokinetics of antipyrine and the urinary excretion of antipyrine and its three major metabolites (4-hydroxyantipyrine, norantipyrine, and 3-hydroxymethylantipyrine) in 12 patients with extensive metastatic liver disease, and in 12 matched healthy controls. In the patients total liver volume, the volume of the liver parenchyma, and the volume of the liver metastases were determined by computed tomography. The volume of liver metastases always exceeded 35% of the total liver volume. There were no significant differences between the patients and controls in plasma half-life, plasma clearance, or apparent volume of distribution of antipyrine. The cumulative urinary excretion of antipyrine and its three major metabolites was significantly lower in patients [44 (18) %] than in controls [71 (8) %]. The excretion of antipyrine itself was unchanged and the decrease in cumulative excretion was due to reduced excretion of the three metabolites. The results show that the activity of the hepatic mixed function oxidases was not impaired even in patients with extensive metastatic liver disease. This may be because liver metastases do not cause a corresponding reduction in the volume of normal hepatic parenchyma. The decreased urinary excretion of the three major metabolites of antipyrine, which are mainly glucuronidated, may have been due to an alteration in the process of conjugation.
authors.affiliation: Department of Medicine, University of Bonn, Bonn-Venusberg, FRG.
authors.forename: G M
authors.initials: GM
authors.lastname: Robertz-Vaupel
authors.forename: K D
authors.initials: KD
authors.lastname: Lindecken
authors.forename: T
authors.initials: T
authors.lastname: Edeki
authors.forename: C
authors.initials: C
authors.lastname: Funke
authors.forename: S
authors.initials: S
authors.lastname: Belwon
authors.forename: H J
authors.initials: HJ
authors.lastname: Dengler
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000556:secondary*; D000368:Aged; D000983:Antipyrine / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics*; D015179:Colorectal Neoplasms / Q000473:pathology; D000077553:Edaravone; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology / Q000556:secondary*; D008297:Male; D008875:Middle Aged
chemical_list: C007983:4-hydroxyantipyrine; C031820:3-hydroxymethylantipyrine; D000077553:Edaravone; D000983:Antipyrine